In primed murine bone marrow-derived macrophages challenged with cholesterol crystals, febuxostat reduced intracellular uric acid and ROS signals and suppressed inflammatory mediator release at the tested micromolar concentrations. Reduced LDH release accompanied these effects; the findings apply to this stimulation model. [2]
Febuxostat inhibition of soluble and heparin-bound XO
Biochemical assay · Purified XO free in solution or immobilized on heparin-Sepharose 6B (HS6B). [1]
The authors reported similar inhibition constants for soluble and HS6B-bound XO at pH 7.4. These are Dixon-plot estimates from urate formation, not cellular IC50 values or treatment doses.
Literature-Reported Treatment Conditions
- Treatment concentration
- Varied nanomolar febuxostat; xanthine at 10 and 100 μM.
- Method
- Dixon analysis of initial urate-formation rates; Figure 4 specifies XO or HS6B-XO at 2 mU/ml, 5 mM KPi, pH 7.4, detection at 295 nm.
- Reported limits
- Figure 4 caption specifies 5 mM KPi and 295 nm, whereas general Enzyme Analysis specifies 50 mM KPi and 292 nm. Values are attributed to Figure 4 without reconciling these reporting differences. Assay duration, inhibitor vehicle and uncertainty of Ki are not given for Figure 4.
Methods and source locations
Compound reported in the paper: Febuxostat; Compound label in the paper: Febuxostat
Compound-level research findings in the reported model; material from the cited study was not an Adooq lot.
Figure 4A–B and caption; Results: Kinetic analysis; Materials and Methods: Materials, Enzyme Analysis and HS6B binding
Urate formation by soluble XO: Dixon plot, two xanthine concentrations. — Figure 4A and caption; Results: Kinetic analysis
Urate formation by HS6B-bound XO: Dixon plot, two xanthine concentrations. — Figure 4B and caption; Results: Kinetic analysis
Cholesterol crystal responses in murine macrophages
Cell-based study · Pam3CSK4-primed bone marrow-derived macrophages from wild-type C57BL/6 mice, challenged with cholesterol crystals. [2]
Febuxostat reduced crystal-induced uric acid and ROS signals and reduced cytokine/chemokine secretion under these conditions. LDH release was reduced, supporting a protective effect in this assay rather than proving general absence of cytotoxicity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 and 200 μM febuxostat for cytokine assays; 200 μM for uric acid, ROS and LDH panels.
- Exposure duration
- 30 min crystal challenge for uric acid/ROS; 6 h for cytokine/chemokine and LDH assays.
- Method
- Overnight Pam3CSK4 priming (100 ng/mL), followed by cholesterol crystals (1 mg/mL). ROS methods specify 10–15 min inhibitor pretreatment; this interval is not assigned to other endpoints.
- Co-treatment
- Febuxostat was tested with the priming/crystal challenge. NAC, apocynin and z-VAD-fmk were separate comparator conditions.
- Reported limits
- Figure 5 vehicle is labeled but its composition is not specified in the read text. Cytokine-assay inhibitor pretreatment interval and exact replicate/well counts are not specified. Macrophage febuxostat supplier/form is not separately stated.
Methods and source locations
Compound reported in the paper: Febuxostat; Compound label in the paper: Febuxostat
Compound-level research findings in the reported model; material from the cited study was not an Adooq lot.
Figure 5A–G and caption; Results: Cholesterol crystals enhance macrophage inflammatory cytokine secretion via XO and ROS; Methods: BMDM, cell stimulation, ROS, uric acid, ELISA, LDH and statistics
Crystal-induced intracellular uric acid and ROS accumulation: Uric acid/uricase assay normalized to protein; fluorescent intracellular ROS assay. Panels represent three independent experiments, mean ± SEM; exact within-experiment n not specified. — Figure 5A–B and caption; Methods: intracellular uric acid and ROS
Secreted IL-1β, MCP-1, IL-1α and IL-6 after crystal challenge: Supernatant ELISA, 6 h. Representative of three independent experiments, mean ± SEM. Vehicle/medium and vehicle/crystal controls; separate ROS-scavenger and caspase-inhibitor comparators. — Figure 5C–F and caption; corresponding Results and Cell stimulation/ELISA methods
Crystal-induced LDH release: LDH release normalized to Triton X-100 lysis reference, with background subtraction; representative of three independent experiments, mean ± SEM. — Figure 5G and caption; Methods: Measurement of LDH